CoChat

Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Background: Prazosin has been an accepted treatment for patients with post-traumatic stress disorder (PTSD) who experience sleep disturbances, including nightmares. Results of a recent large randomized control trial did not find benefit of prazosin vs placebo in improving such outcomes. A meta-analysis that includes this most recent trial was conducted to examine the pooled effect of prazosin vs placebo on sleep disturbances and overall PTSD symptoms in patients with PTSD. Methods: A systematic review of the published literature on trials comparing prazosin vs placebo for improvement of overall PTSD scores, nightmares, and sleep quality was conducted. Hedges’ g standardized mean differences (SMD) between prazosin and placebo were calculated for each outcome across studies. Results: Six randomized placebo-controlled studies representing 429 patients were included in the analysis, including two studies with a crossover design. Results showed prazosin significantly improved overall PTSD scores (SMD = −0.31; 95% confidence intervals [CI]: −0.62, −0.01), nightmares (SMD = −0.75; 95% CI: −1.24, −0.27), and sleep quality (SMD = −0.57; 95% CI: −1.02, −0.13). In the largest trial, prazosin showed a reduction in clinical outcome measures similar to past studies, but a relatively large placebo effect size, particularly for nightmares, contributed to no treatment differences. Conclusions: Despite the results of a recent, large randomized study, pooled effect estimates show that prazosin has a statistically significant benefit on PTSD symptoms and sleep disturbances. Limitations that should be considered include heterogeneity of study design and study populations as well as the small number of studies conducted and included in this meta-analysis.

Overview

Integrity signals

Registry

Crossref · 10.1017/s1092852920001121

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 3

  1. Glue, 2018, Prazosin for post-traumatic stress disorder, N Engl J Med, 378, 1649
  2. Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions Vol. Version 5.1.0
  3. Mysliwiec, 2018, Prazosin for post-traumatic stress disorder, N Engl J Med, 378, 1649

Cited by

See all 61

Metadata

Authors
Reist, C., Streja, E., Tang, C. C., Shapiro, B., Mintz, J., & Hollifield, M.
Affiliations
  • University of California, Irvine (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • Tibor Rubin VA Medical Center (US)
Corresponding author
Reist, Christopher
Venue
CNS Spectrums
Published
2020-05-04
Volume
26
Issue
4
Pages
338-344
ISSN
  • 1092-8529 (ISSN-L)
  • 2165-6509
OpenAlex
W3023536591
Cited by
56
References
37
Citations by year
2026: 4 · 2025: 9 · 2024: 17 · 2023: 13 · 2022: 7 · 2021: 5 · 2020: 1
FWCI
0.51
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Spectrums (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
Keywords
prazosin, post-traumatic stress disorder, nightmares, sleep disorders, sleep quality, placebo effect, alpha-blockers, PTSD symptom severity
MeSH terms
Humans, Prazosin, Stress Disorders, Post-Traumatic, Treatment Outcome, Adrenergic alpha-1 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1017/s1092852920001121
The paper
Reist, C., Streja, E., Tang, C. C., Shapiro, B., Mintz, J., & Hollifield, M. (2021). Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectrums. https://doi.org/10.1017/s1092852920001121

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.